NCT00564941已完成4 期
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 309
- 试验地点
- 1
- 主要终点
- This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overload
研究概览
简要总结
This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overload
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Deferasirox
Experimental
干预措施: deferasirox (Drug)
结局指标
主要结局
This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overload
时间窗: monthly during the therapy and at the end of the treatment (aftr 9 months therapy)
次要结局
- patient's compliance during the study assessed by the number of the unused tablets returned by the patient safety assessed by patient laboratory data, adverse events, serious adverse events(during the treatment (9 months))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.Myelodysplastic SyndromeThalassemiaNCT01250951Novartis Pharmaceuticals111
已完成
2 期
Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension StudyNon-transfusion Dependent ThalassemiaNCT00873041Novartis Pharmaceuticals166
已完成
3 期
Safety, Tolerability, and Efficacy of Deferasirox in MDSMyelodysplastic SyndromesHemosiderosisNCT00469560Gruppo Italiano Malattie EMatologiche dell'Adulto158
已完成
2 期
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic PatientsIron OverloadMyelodysplastic SyndromeNCT00110266Novartis Pharmaceuticals176
已完成
4 期
Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent ThalassemiaNon-transfusion Dependent ThalassemiaNCT01709838Novartis Pharmaceuticals134